Clinical trials: Atrophy
Parkinson Disease, MSA - Multiple System Atrophy
Differential Diagnosis Between Parkinson's Disease and Multiple System Atrophy Using Digital Speech Analysis
Parkinson's disease (PD) is the second most common neurodegenerative disease. Multiple system atrophy (MSA) is a relentlessly progressing rare neurodegenerative disease of unknown etiology.
- Trial name
- Voice4PD-MSA (NCT03577483)
- Testing
- voice recordings
- Where
- 2 sites in France
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Atrophy
Quantifying Quadriceps Atrophy Following Tibial Plateau Fracture
This study will quantify and examine the extent to which the quadriceps femoris muscle group atrophies following tibial plateau fractures and the length of time that atrophy affects function.
- Trial name
- NCT02781623
- Testing
- MRI
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- NYU Langone Health
Disuse Atrophy (Muscle) of Lower Extremities, Muscle Function
The Impact of Bed Rest, Aging and NMES on Skeletal Muscle
Loss of muscle mass is common phenotypic trait of muscular disuse and ageing. The loss of muscle mass affects, among others, the ability to maintain homeostasis of glucose metabolism and the energy reservoir in catabolic…
- Conditions
- Disuse Atrophy (Muscle) of Lower Extremities, Muscle Function, Neuromuscular Electrical Stimulation, Myofibrillar Protein Synthesis
- Trial name
- NCT05617222
- Testing
- Bed rest, Neuromuscular electrical stimulation
- Where
- Denmark
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bispebjerg Hospital
Assessment, Self, Muscle Atrophy
Correlation of Muscle Ultrasound Measures (2D and 3D) With Biphotonic X-ray Absorptiometry in Oldest Old Patients.
The sarcopenia diagnosis is based on the muscle mass and on impaired physical performance. The emerging field of ultrasound assessment of muscle mass in older patients is based on 2d parameters with prediction equations for…
- Conditions
- Assessment, Self, Muscle Atrophy, Ultrasound Therapy; Complications, Aging
- Trial name
- DIASEM (NCT04753450)
- Testing
- No intervention
- Where
- France
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital
Leber's Hereditary Optic Neuropathy (LHON)
Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy
The objective of this clinical study is to select the optimal dose and evaluate the safety and efficacy of NR082 in treatment of LHON caused by mitochondrial ND4 gene mutation.
- Trial name
- GOLD (NCT04912843)
- Testing
- NR082 injection
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Wuhan Neurophth Biotechnology Limited Company
Spinal Muscular Atrophy
Metabolomics of Children With SMA
The aim of the proposed project is to evaluate whether the metabolome of patients with spinal muscular atrophy (SMA) before the initiation of treatment with nusinersen differs from the metabolome of healthy individuals and…
- Trial name
- NCT04587492
- Testing
- Nusinersen
- Where
- 2 sites in Slovenia
- Volunteers
- 35 people
- Sponsor
- University Medical Centre Ljubljana
Old Age; Atrophy, Elderly
Relationship Occupation and Physical Performance in Elderly
Occupational competence indicates participating in a variety of occupations to meet the standards expected of the individuals' valued roles to sustain a pattern of occupational attitudes that is significant and satisfying.
- Conditions
- Old Age; Atrophy, Elderly, Occupational Balance, Postural Balance
- Trial name
- NCT05609851
- Testing
- Short Physical Performance Batary, Occupational Balance Self-Assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Gaziantep
Geographic Atrophy
Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)
This is a prospective, randomized study to evaluate the efficacy and safety of ORACEA® in the treatment of geographic atrophy due to dry age-related macular degeneration (AMD).
- Trial name
- TOGA (NCT01782989)
- Testing
- ORACEA®
- Where
- 37 sites in United States
- Volunteers
- 286 people
- Sponsor
- Paul Yates, MD, PhD
Parkinson Disease, MSA - Multiple System Atrophy
Manipulating and Optimising Brain Rhythms for Enhancement of Sleep
Treatment of sleep disturbances is mainly attempted through drug administration. However, certain drugs are associated with unwanted side effects or residual effects upon awakening (e.g.
- Conditions
- Parkinson Disease, MSA - Multiple System Atrophy, Chronic Pain, Epilepsy
- Trial name
- MORPHEUS (NCT05011773)
- Testing
- Deep brain stimulation
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- University of Oxford
Multiple System Atrophy, Autonomic Failure
Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy
Patients referred to neurosurgery routinely and safely undergo deep brain stimulation (DBS) for treatment of symptoms related to neurodegenerative conditions, most commonly Parkinson's disease.
- Conditions
- Multiple System Atrophy, Autonomic Failure, Postural Hypotension, Bladder, Neurogenic
- Trial name
- STAG-MSA (NCT03593512)
- Testing
- Deep brain stimulation
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- University of Oxford
Muscle Tone Poor, Spinal Muscular Atrophy
Myotonometer Intra- and Inter Examiner Reliability on Spinal Muscular Atrophy
The primary aim of the study was to measure the intra-rater and inter-rater reliability of MyotonPRO in measuring postural muscle tone and mechanical properties in individuals with spinal muscular atrophy (SMA).
- Trial name
- NCT05521217
- Testing
- MyotonPRO
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Istanbul Medipol University Hospital
Spinal Muscular Atrophy
Spinal Muscular Atrophy on Wheels, Using Power Mobility
The group of children diagnosed with Spinal Muscular Atrophy (SMA) has serious restrictions on participation. SMA is a neuromuscular disease that leads to neuromusculoskeletal disorders that limit functional activities, sometimes…
- Trial name
- SMAPmob (NCT05589987)
- Testing
- power mobility
- Where
- 2 sites in Spain
- Volunteers
- 20 people
- Sponsor
- University of Castilla-La Mancha
Sarcopenia, Muscular Atrophy
The Effects of Home-based Physical Activity Telemonitoring Program in Patients With Heart Failure and Muscle Wasting
Introduction： Muscle wasting is a serious complication that affects a large proportion of patients with heart failure (HF). Muscle wasting is a strong predictor of frailty and reduced survival in HF patients.
- Conditions
- Sarcopenia, Muscular Atrophy, Wasting Syndrome, Heart Failure
- Trial name
- NCT05588375
- Testing
- home-based physical activity telemonitoring program
- Where
- Taiwan
- Volunteers
- 118 people
- Sponsor
- Far Eastern Memorial Hospital
Multiple System Atrophy (MSA)
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)
The purpose of this expanded access program is to provide access to the investigational drug verdiperstat in patients with Multiple System Atrophy (MSA).
- Trial name
- NCT05086094
- Testing
- BHV3241, verdiperstat
- Where
- United States
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Atrophy
Morphological and Functional Evaluation of Buttock Lipoatrophy Treatment With Macrolane
The study is being undertaken to establish the effectiveness and safety of Macrolane volume restoration factor 30 (VRF30) when used for treatment of HIV-infected subjects with buttocks lipoatrophy.
- Trial name
- NCT00931268
- Testing
- Macrolane VRF 30
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Galderma R&D
Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
This multiple-center, 3-part, single-blind dose escalation (Part A), randomized, double-blind (Part B), and open-label multiple dose extension (Part C) study will be conducted in male and female subjects with neurogenic…
- Conditions
- Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease
- Trial name
- NCT02705755
- Testing
- TD-9855
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Theravance Biopharma
Dry Age-related Macular Degeneration, Geographic Atrophy
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration
This study is designed to investigate the safety, PK/PD, biomarker and early clinical effects of repeat GEM103 IVT injections.
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease
- Trial name
- NCT04643886
- Testing
- GEM103
- Where
- 29 sites in United States
- Volunteers
- 62 people
- Sponsor
- Gemini Therapeutics, Inc.
Soft Tissue Atrophy
Increasing the Thickness of Soft Tissues in the Esthetic Zone Around Implants
This is an interventional prospective randomized clinical trial (RCT) in parallel groups. This study is aimed at detecting a difference in the increase in the thickness of soft tissues of at least 0.3 mm between the two groups…
- Trial name
- NCT05551962
- Testing
- Soft tissue augmentation with CTG, Soft tissue augmentation with CM
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Spinal Muscular Atrophy, Quality of Life
Reliability and Validity of the Turkish Version of the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old
The aim of the investigator's study was to investigate translating the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old and using it in clinics reliably and validity with a Turkish version of the PedsQL Generic Core…
- Conditions
- Spinal Muscular Atrophy, Quality of Life, Neuromuscular Diseases, Pediatric Disorder
- Trial name
- NCT05539456
- Where
- Turkey (Türkiye)
- Volunteers
- 55 people
- Sponsor
- Istanbul Medipol University Hospital
Spinal Muscular Atrophy 1
Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1
The purpose of this trial is to evaluate safety and efficacy of intravenous delivery of AVXS-101 as a treatment of spinal muscular atrophy Type 1 (SMN1).
- Trial name
- NCT02122952
- Testing
- AVXS-101
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Novartis Gene Therapies